MEMORANDUM

TO: Faculty engaged in research supported by pharmaceutical or device firms and other for-profit entities

FROM: Kimberly Summers, PharmD
       Director of Research Regulatory Programs

RE: IRB and IACUC Review Fees

Research supported by pharmaceutical or device firms and other for-profit entities conducted by UTHSCSA faculty and staff will be charged at the following rates:

Research reviewed by the UTHSCSA IRB
   • Initial review fee $3,500
   • Review fee $1,000 for all re-approvals

Research reviewed by an approved outside IRB
   • Initial review fee $2,500
   • Review fee $1,000 for all re-approvals

The fee will NOT apply to applications submitted to the IRB that:
   • Do not (a) constitute research or (b) involve human subjects
   • Qualify for exemption from IRB review
   • Are solely or primarily federally funded
   • Involve a non-research use of a Humanitarian Use Device
   • Are for emergency use or expanded access of an investigational drug or device
   • Are supported by Pharmaceutical Companies in which the UTHSCSA investigator holds the intellectual property and NO information will be shared with the for-profit company

For research in which the UTHSCSA investigator shares the intellectual property with the for-profit company, contact the Director of Research Regulatory Programs for associated fees.

Research reviewed by the UTHSCSA IACUC
   • Initial review fee $2,000
   • Review fee $500 for all re-approvals

Research reviewed by an approved outside IACUC
   • Initial review fee $1,500
   • Review fee $500 for all re-approvals

Studies supported by for-profit entities will be billed/collected by the UTHSCSA Clinical Trials Office (CTO); researchers need to account for the applicable review fees in their proposed budgets.